{"id":31884,"date":"2025-04-16T11:24:28","date_gmt":"2025-04-16T03:24:28","guid":{"rendered":"https:\/\/flcube.com\/?p=31884"},"modified":"2025-04-16T11:24:29","modified_gmt":"2025-04-16T03:24:29","slug":"cyprumed-signs-non-exclusive-license-agreement-with-msd-for-oral-peptide-delivery-tech","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31884","title":{"rendered":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech"},"content":{"rendered":"\n

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK<\/a>). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.<\/p>\n\n\n\n

Agreement Terms and Financials<\/strong>
Under the agreement, MSD secures non-exclusive global rights to utilize Cyprumed\u2019s oral peptide delivery platform for an undisclosed number of targets. Additionally, MSD holds the option to exclusively license the technology for individual targets. Cyprumed stands to benefit from significant financial milestones, with potential payments totaling up to USD 493 million, including upfront, development, regulatory, and net sales milestones. Further payments may be triggered if MSD exercises its exclusive license option.<\/p>\n\n\n\n

Technology and Market Potential<\/strong>
Cyprumed\u2019s oral peptide delivery platform represents a breakthrough in drug delivery, addressing the challenges traditionally associated with oral administration of peptide-based drugs. This technology could significantly enhance patient compliance and convenience by offering a viable alternative to injectable formulations. MSD\u2019s investment highlights the growing interest in oral peptide therapies and their potential to disrupt the market.<\/p>\n\n\n\n

Development and Commercialization<\/strong>
MSD will be responsible for all aspects of research, development, manufacturing, and commercialization of products leveraging Cyprumed\u2019s delivery technology. This comprehensive approach ensures that MSD can fully harness the potential of Cyprumed\u2019s platform to bring novel oral peptide formulations to market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp…<\/p>\n","protected":false},"author":1,"featured_media":31886,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4001,2675,176,903],"class_list":["post-31884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cyprumed","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"\nCyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31884\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech\" \/>\n<meta property=\"og:description\" content=\"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31884\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T03:24:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T03:24:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech\",\"datePublished\":\"2025-04-16T03:24:28+00:00\",\"dateModified\":\"2025-04-16T03:24:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1601-1.webp\",\"keywords\":[\"Cyprumed\",\"Merck Sharp & Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31884#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31884\",\"name\":\"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1601-1.webp\",\"datePublished\":\"2025-04-16T03:24:28+00:00\",\"dateModified\":\"2025-04-16T03:24:29+00:00\",\"description\":\"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31884\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1601-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1601-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31884#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech - Insight, China's Pharmaceutical Industry","description":"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31884","og_locale":"en_US","og_type":"article","og_title":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech","og_description":"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.","og_url":"https:\/\/flcube.com\/?p=31884","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T03:24:28+00:00","article_modified_time":"2025-04-16T03:24:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31884#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31884"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech","datePublished":"2025-04-16T03:24:28+00:00","dateModified":"2025-04-16T03:24:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31884"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","keywords":["Cyprumed","Merck Sharp & Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31884#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31884","url":"https:\/\/flcube.com\/?p=31884","name":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31884#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31884#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","datePublished":"2025-04-16T03:24:28+00:00","dateModified":"2025-04-16T03:24:29+00:00","description":"Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp & Dohme (MSD; NYSE: MRK). This strategic partnership grants MSD access to Cyprumed\u2019s innovative drug delivery technology to develop oral formulations of its peptides, potentially transforming the delivery of peptide-based therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31884#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31884"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31884#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","width":1080,"height":608,"caption":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31884#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1601-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31884"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31884\/revisions"}],"predecessor-version":[{"id":31887,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31884\/revisions\/31887"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31886"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}